Online citations, reference lists, and bibliographies.
← Back to Search

Vaccine Delivery Using Nanoparticles

A. Gregory, R. Titball, D. Williamson
Published 2013 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens.
This paper references
10.1016/J.JCONREL.2006.01.012
Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.
L. Feng (2006)
J. Pharm. Sci
10.1038/nrmicro1681
The perfect mix: recent progress in adjuvant research
B. Guy (2007)
10.1016/0264-410X(89)90164-3
Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).
S. Pyle (1989)
Microbial degradation of poly
M Obst (2004)
10.1042/BJ20031253
Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis.
J. Rejman (2004)
10.1016/S0065-3527(06)68005-6
Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins.
R. Harrison (2006)
10.1016/j.biomaterials.2009.05.045
Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres.
Helena F. Florindo (2009)
HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
L. Åkerblom (1993)
10.3109/02652048.2010.529947
Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: an in vitro/in vivo evaluation in induced colitis in rat
J. Varshosaz (2011)
Soluble proteins
G. Reid (1992)
HPV 16 / 18 L 1 VLP
T. J. Kemp (2011)
10.1128/JVI.75.13.6223-6227.2001
Novel Baculovirus Expression Vectors That Provide Sialylation of Recombinant Glycoproteins in Lepidopteran Insect Cells
D. Jarvis (2001)
10.1016/0264-410X(91)90193-A
Biochemical characterization of herpes simplex virus type-1-immunostimulating complexes (ISCMOs): a multi-glycoprotein structure.
M. Erturk (1991)
10.1016/J.VETIMM.2005.05.004
Use of biodegradable PLGA microspheres as a slow release delivery system for the Boophilus microplus synthetic vaccine SBm7462.
P. Sales-Junior (2005)
10.1016/J.VACCINE.2006.04.068
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
L. Villa (2006)
10.1016/S0264-410X(02)00536-4
Liposomal delivery of antigen to human dendritic cells.
M. J. Copland (2003)
J. Control. Release
DepoVax enhance efficacy of in vivo nucleic acid delivery
10.1046/j.1365-3024.1997.d01-197.x
Intranasal immunization of mice with Echinococcus granulosus surface antigens Iscoms evokes a strong immune response, biased towards glucidic epitopes
H. Carol (1997)
10.1016/j.vaccine.2010.07.025
A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery.
Mohan Karkada (2010)
10.1246/CL.2004.398
Stably-dispersed and Surface-functional Bionanoparticles Prepared by Self-assembling Amphipathic Polymers of Hydrophilic Poly(γ-glutamic acid) Bearing Hydrophobic Amino Acids
MatsusakiMichiya (2004)
10.1016/j.biomaterials.2009.11.100
Multifunctional core-shell polymeric nanoparticles for transdermal DNA delivery and epidermal Langerhans cells tracking.
Po-Wei Lee (2010)
10.1016/J.IJPHARM.2004.07.021
Design and process aspects of laboratory scale SCF particle formation systems.
Chandra Vemavarapu (2005)
10.1021/bc100367u
Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry.
Kedar G. Patel (2011)
10.2105/AJPH.25.3.298
Some Observations on the Use of Alum Precipitated Diphtheria Toxoid.
W. Harrison (1935)
10.1016/S0264-410X(96)00073-4
In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid.
R. K. Gupta (1996)
10.1016/j.vaccine.2009.12.084
Vaccine adjuvants: a priority for vaccine research.
A. Harandi (2010)
10.1086/320190
A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.
T. Evans (2001)
Int. J. Pharm
Immunostimulating complexes. Clinical potential in vaccine development
10.1371/journal.pone.0034226
SweetBac: A New Approach for the Production of Mammalianised Glycoproteins in Insect Cells
Dieter Palmberger (2012)
10.1016/J.NANTOD.2011.02.003
Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies
T. Iversen (2011)
10.1056/NEJMOA020586
A controlled trial of a human papillomavirus type 16 vaccine.
L. Koutsky (2002)
10.1016/J.EJPB.2006.11.009
A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes.
K. Letchford (2007)
Res
Lancet Oncol
10.1038/nri2868
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
M. Bachmann (2010)
10.1073/PNAS.0600997103
Role of target geometry in phagocytosis.
J. Champion (2006)
10.1021/LA0513712
Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview.
R. Shukla (2005)
10.1016/J.JCIS.2005.03.088
Surface modification of liposomes by saccharides: vesicle size and stability of lactosyl liposomes studied by photon correlation spectroscopy.
JunMin Zhu (2005)
10.1016/S0168-3659(02)00127-X
Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake.
S. Sahoo (2002)
Rate of disappearance of diptheria toxoid injected into rabbits and guinea pigs: toxoid precipitation with alum
A. T. Glenny (1931)
Approaches to safe nanotechnology
G. Oberdorster (2006)
10.1016/j.ejpb.2011.09.009
Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.
Andrei Soliakov (2012)
10.1517/17425247.2010.488687
Liposomes as delivery systems for nasal vaccination: strategies and outcomes
B. Heurtault (2010)
10.1007/BF03259065
Immunostimulating Complexes
Dr Bror Morein (2012)
10.1002/SMLL.200400093
Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity.
E. E. Connor (2005)
10.1517/17425247.2011.558081
Liposomal vaccine delivery systems
M. Henriksen-Lacey (2011)
target - ing human papillomavirus Types 6 , 11 , 16 , and 18
C. Villiers (2010)
Pharm. Res
10.1023/A:1020452531828
Analysis of Poly(D,L-Lactic-Co-Glycolic Acid) Nanosphere Uptake by Human Dendritic Cells and Macrophages In Vitro
M. E. C. Lutsiak (2004)
10.1016/J.JCONREL.2006.04.006
Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Sudhir Pai Kasturi (2006)
10.1016/J.VIROL.2006.12.014
Human immunodeficiency virus-like particles activate multiple types of immune cells.
G. Sailaja (2007)
10.1136/VR.117.2.37
A bovine ephemeral fever vaccine incorporating adjuvant Quil A: a comparative study using adjuvants Quil A, aluminium hydroxide gel and dextran sulphate
B. Vanselow (1985)
10.1093/INTIMM/9.4.523
In vivo induction of type 1 and 2 immune responses against protein antigens.
E. Comoy (1997)
10.1021/nl901534q
Long-term persistence and spectral blue shifting of quantum dots in vivo.
James A. J. Fitzpatrick (2009)
10.1515/REVCE.2005.21.1.33
SUPERCRITICAL FLUID TECHNIQUE FOR PARTICLE ENGINEERING: DRUG DELIVERY APPLICATIONS
E. D. Valle (2005)
A phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus type 11 in healthy adult volunteers
T G Evans (2001)
10.1016/0264-410X(94)90154-6
Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.
P. de Vries (1994)
10.1586/erm.09.15
Current advances in research and clinical applications of PLGA-based nanotechnology
J. Lü (2009)
10.1023/A:1018908705446
Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles
R. Fernández-Urrusuno (2004)
10.1016/S0264-410X(02)00435-8
Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.
I. Gutierro (2002)
10.1016/0304-4157(95)00002-9
Liposomes and ISCOMS as vaccine formulations.
G. Kersten (1995)
Vaccine delivery using nanoparticles
AE Citation Gregory (2013)
Vaccine design : the subunit and adjuvant approach
M. F. Powell (1995)
10.1016/0264-410X(92)90439-Q
Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid.
G. Reid (1992)
10.1002/1097-4628(20001003)78:1<140::AID-APP180>3.0.CO;2-P
In vitro degradation and release profiles of poly-DL-lactide-poly(ethylene glycol) microspheres with entrapped proteins
X. Li (2000)
10.1007/s11095-007-9257-9
Chitosan Reduced Gold Nanoparticles as Novel Carriers for Transmucosal Delivery of Insulin
D. Bhumkar (2007)
10.1021/nn900918w
Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs.
T. Xia (2009)
10.1093/NDT/17.SUPPL_2.17
The potential role of aluminium in Alzheimer's disease.
A. Campbell (2002)
10.1016/J.VACCINE.2003.12.032
Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.
Praveen Elamanchili (2004)
10.1016/S0042-6822(03)00120-X
Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production.
D. Jarvis (2003)
10.1016/0264-410X(88)90174-0
Polyvalent recombinant antigens: a new vaccine strategy.
S. Kingsman (1988)
10.1007/978-3-540-69379-6_1
Chemical modification of viruses and virus-like particles.
E. Strable (2009)
10.1016/S0169-409X(02)00046-7
Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.
T. Merdan (2002)
Drug Deliv
10.1007/s11095-008-9626-z
Shape Induced Inhibition of Phagocytosis of Polymer Particles
J. Champion (2008)
10.1016/j.vaccine.2011.01.001
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
T. Kemp (2011)
10.1016/0889-1605(89)90018-9
Quaternary structure of the immunostimulating complex (iscom).
M. Ozel (1989)
10.1016/0264-410X(94)90288-7
Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs.
M. Kazanji (1994)
10.1073/PNAS.90.24.11478
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
E. Fynan (1993)
10.1073/PNAS.89.1.358
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.
L. Fries (1992)
10.1016/j.exppara.2012.04.017
Poly D,L-lactide-co-glycolic acid (PLGA)-encapsulated vaccine on immune system in Epinephelus bruneus against Uronema marinum.
R. Harikrishnan (2012)
10.1016/0264-410X(93)90377-A
Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines.
N. Goto (1993)
疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A
宁北芳 (2005)
Prophylactic antitumor effects in a B cell lymphoma model with DNA vaccines
S. Pai Kasturi (2006)
Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis
M. Kazanji (1994)
10.1128/IAI.56.2.432-438.1988
Incorporation of the major outer membrane protein of Neisseria gonorrhoeae in saponin-lipid complexes (iscoms): chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems.
G. Kersten (1988)
10.1038/sj.gt.3302193
DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration
S. Takamura (2004)
10.1021/mp200572t
Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations.
K. Sonaje (2012)
10.1002/SMLL.200500104
Cellular uptake and toxicity of Au55 clusters.
Maria Tsoli (2005)
10.1517/17425247.3.3.345
Immunostimulatory colloidal delivery systems for cancer vaccines
A. Saupe (2006)
10.1046/j.1365-2567.2001.01337.x
Interleukin‐1β, but not interleukin‐1α, is required for T‐cell‐dependent antibody production
S. Nakae (2001)
10.1016/j.ejps.2011.10.012
Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant.
T. Wang (2011)
10.1016/J.VACCINE.2006.11.049
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
K. Slupetzky (2007)
Eur. J. Pharm. Biopharm
10.1016/j.clim.2009.03.035
OR.28. Aluminum Hydroxide Adjuvants Activate the Immune System Through the Nalp3 Inflammasome
Stephanie C Eisenbarth (2009)
10.1016/0264-410X(85)90055-6
Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes.
B. Morein (1985)
Immunization with virus-like particles prevents bovine papillomavirus type 4 mucosal infection of calves
R Kirnbauer (1996)
10.1289/ehp.94102s5173
Correlation between particle size, in vivo particle persistence, and lung injury.
G. Oberdörster (1994)
10.1016/j.immuni.2011.04.003
Getting closer to the dirty little secret.
Karin Pelka (2011)
10.1080/026520400405732
Influence of various technological parameters on the preparation of spray-dried poly(epsilon-caprolactone) microparticles containing a model antigen.
B. Baras (2000)
10.1111/j.1365-2567.2005.02268.x
Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles
H. Shen (2006)
10.1021/ja9071282
Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.
Shanta Dhar (2009)
10.1042/BJ20040007
Enhancement of correct protein folding in vivo by a non-lytic baculovirus.
Y. Ho (2004)
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution,andreproductioninanymedium,providedtheoriginalauthorandsourcearecredited.Thislicensedoesnot permit commercial exploitation or the creation of derivative works without sp
M. Waters (2009)
10.1016/j.ymeth.2006.07.018
Virus-like particles: Passport to immune recognition
E. Grgacic (2006)
10.1177/003463736506200107
From the U. S. A.
Elmer S. West (1965)
Developments in Diptheria Prophylaxis
L. B. Holt (1950)
10.1016/S0378-5173(02)00548-3
Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles.
Y. Xu (2003)
10.1016/J.IJPHARM.2005.03.035
Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.
C. Foged (2005)
10.1016/0264-410X(92)90437-O
Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies.
M. Browning (1992)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1016/j.nano.2008.05.006
Novel nanoparticles for the delivery of recombinant hepatitis B vaccine.
D. Bharali (2008)
10.1080/026520401750038557
Mucoadhesive chitosan-coated liposomes: characteristics and stability
J. Filipović‐Grčić (2001)
Frontiers in Cellular and Infection Microbiology www.frontiersin.org March 2013 | Volume 3 | Article 13 | 12 characterization
10.1002/SMLL.200700378
Size-dependent cytotoxicity of gold nanoparticles.
Y. Pan (2007)
10.1016/0264-410X(95)00262-Y
Protective immunity induced in chicken by a single immunization with Mycoplasma gallisepticum immunostimulating complexes (ISCOMS).
B. Sundquist (1996)
Frontiers in Cellular and Infection Microbiology www.frontiersin.org
(2013)
10.1007/S11051-009-9692-0
Analysis of the toxicity of gold nano particles on the immune system: effect on dendritic cell functions
C. Villiers (2010)
10.1016/J.BIOMATERIALS.2007.02.021
Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway.
S. Lai (2007)
10.1093/GLYCOB/8.5.473
Stable expression of mammalian beta 1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells.
J. R. Hollister (1998)
10.1016/J.ADDR.2004.09.008
Immunity in response to particulate antigen-delivery systems.
T. Storni (2005)
Influence of various technological parameters on the preparation of spraydried poly(epsilon-caprolactone
B. Baras (2000)
Curr. Opin. Solid State Mater. Sci
10.1016/J.BIOMATERIALS.2007.09.007
The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccine.
Xianfeng Zhou (2008)
10.4049/jimmunol.0900164
Alum Induces Innate Immune Responses through Macrophage and Mast Cell Sensors, But These Sensors Are Not Required for Alum to Act As an Adjuvant for Specific Immunity1
Amy S McKee (2009)
10.1002/JPS.1143
Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles.
J. F. Hillyer (2001)
10.1016/S0141-3910(97)00175-4
Biodegradation of polyamides
F. B. Oppermann (1998)
10.1089/AID.1992.8.1765
The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants.
R. Bomford (1992)
10.1128/JVI.69.6.3959-3963.1995
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
F. Breitburd (1995)
10.1038/mt.2009.281
The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls.
D. Vercauteren (2010)
10.1073/pnas.1004879107
IFN-γ produced by CD8 T cells induces T-bet–dependent and –independent class switching in B cells in responses to alum-precipitated protein vaccine
E. Mohr (2010)
10.1016/S0076-6879(05)91002-1
Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
D. Waterhouse (2005)
Liposomes: A review
S. Shailesh (2009)
Frontiers in Cellular and Infection Microbiology
Y. Ho (2004)
Molecular and cellular control of T1/T2 immunity at the interface between antimicrobial defense and immune
A. Bot (2004)
Chitosangadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy
H. Tokumitsu (1999)
10.1093/INFDIS/171.4.909
Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes.
J. Ma (1995)
10.1016/J.IJPHARM.2006.06.023
PLA/PLGA nanoparticles for sustained release of docetaxel.
T. Musumeci (2006)
10.1016/0264-410X(86)90005-8
Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen.
C. Alving (1986)
10.1111/j.1365-3024.1989.tb00658.x
Lack of interspecies barriers in anti–Id stimulated antibody production against Echinococcus granulosus antigens
H. Carol (1989)
10.1038/NMAT1794
Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery.
Eric P. Holowka (2007)
10.1007/s12033-012-9598-4
Construction and Characterization of Virus-Like Particles: A Review
Andris Zeltiņš (2012)
10.1086/376505
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
L. Pinto (2003)
Immunostimulating complexes . Clinical potential in vaccine development
B. Morein (1985)
Prophylactic quadrivalent human papillomavirus
L. L. Villa (2005)
J. Infect. Dis
10.1007/978-1-61779-621-0
Influenza Virus
K. Hancock (2012)
10.1016/j.imlet.2009.05.008
Modulation of innate and adaptive immunity by biodegradable nanoparticles.
T. Uto (2009)
10.1088/0957-4484/21/19/195101
Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide.
Yangyang Chen (2010)
10.1016/S0168-3659(97)00173-9
Preparation of chitosan self-aggregates as a gene delivery system.
K. Lee (1998)
IFN - γ produced by CD 8 T cells induces T - bet – dependent and – independent class switching in B cells in responses to alum - precipitated protein vaccine
B. Morein (1995)
10.1016/j.biomaterials.2012.03.041
Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.
Stacey L. Demento (2012)
10.1517/13543784.7.3.349
Recent advances in immunological adjuvants: the development of particulate antigen delivery systems.
D. O'hagan (1998)
10.1039/b922291j
Characterization of thiolate-protected gold nanoparticles by mass spectrometry.
Kellen M. Harkness (2010)
10.1016/0005-2736(93)90105-9
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.
G. Haran (1993)
Stable expression of mammalian β1, 4-galactosyltransferase extends the N-glycosylation pathway in insect
J. R. Hollister (1998)
Immunization with virus - like particles prevents bovine papillomavirus type 4 mucosal infection of calves
L. A. Koutsky (2002)
10.1016/S1470-2045(05)70101-7
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
L. Villa (2005)
Interleukin-1 beta, but not interleukin-1 alpha, is required for T-cell-dependent antibody production.
S. Nakae (2001)
10.1016/S0264-410X(02)00169-X
Mechanisms of stimulation of the immune response by aluminum adjuvants.
H. HogenEsch (2002)
10.1016/S0168-3659(98)00148-5
Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation.
H. Sah (1999)
10.5271/SJWEH.3104
Analysis of titanium pigments in human lung tissue.
E. Ophus (1979)
10.1007/978-3-211-74019-4
Fortschritte der Chemie organischer Naturstoffe / Progress in the Chemistry of Organic Natural Products
B. Kräutler (2008)
Immunization with virus-like particles prevents bovine papillomavirus
R. Kirnbauer (1996)
10.1586/erv.10.115
Virus-like particles in vaccine development
A. Roldão (2010)
10.1099/0022-1317-75-8-2097
Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes.
G. Rimmelzwaan (1994)
10.1021/NL052396O
Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells.
B. Chithrani (2006)
10.4049/jimmunol.181.1.17
Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP31
H. Li (2008)
10.1016/S0140-6736(04)17398-4
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
D. Harper (2004)
10.1021/BM049949U
Microbial degradation of poly(amino acid)s.
M. Obst (2004)
10.1016/S0264-410X(00)00394-7
Detoxification of endotoxin by aluminum hydroxide adjuvant.
Y. Shi (2001)
10.1016/S0168-3659(00)00361-8
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency.
H. Mao (2001)
10.1016/J.VACCINE.2007.03.049
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
S. Olsson (2007)
10.1023/A:1016266916893
Characterization of the MN gp120 HIV-1 Vaccine: Antigen Binding to Alum
R. P. Weissburg (2004)
10.1002/cyto.a.20846
Nonendosomal cellular uptake of ligand‐free, positively charged gold nanoparticles
U. Taylor (2010)
10.4049/jimmunol.178.8.5271
Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1β and IL-18 Release1
H. Li (2007)
10.1016/0923-2494(92)80065-S
The iscom structure as an immune-enhancing moiety: experience with viral systems.
I. Claassen (1992)
DNA vaccineencapsulated virus-like particles derived from an orally
S. Takamura (2004)
10.1007/978-1-59745-178-9_2
Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?
A. Ivanov (2008)
10.1016/J.YMETH.2006.05.024
Virus-like particles: designing an effective AIDS vaccine.
Kelly R. Young (2006)
10.1021/BM050204D
Self-assembling bionanoparticles of poly(epsilon-lysine) bearing cholesterol as a biomesogen.
M. Matsusaki (2005)
10.1093/GLYCOB/CWG051
A transgenic insect cell line engineered to produce CMP-sialic acid and sialylated glycoproteins.
J. J. Aumiller (2003)
10.1002/mabi.200800367
Preparation of size tunable amphiphilic poly(amino acid) nanoparticles.
H. Kim (2009)
10.1016/j.otohns.2009.01.045
Strategy
R. Rosenfeld (2009)
10.1016/0005-2736(91)90388-O
On the structure of immune-stimulating saponin-lipid complexes (iscoms).
G. Kersten (1991)
10.1007/12_2011_150
Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine
T. Akagi (2011)
10.1016/j.jconrel.2010.07.116
Polymer particle shape independently influences binding and internalization by macrophages.
G. Sharma (2010)
10.1002/eji.200526285
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity
P. Maurer (2005)
Immunization with virus - like particles prevents bovine papillomavirus type 4 mucosal infection of calves
L. A. Koutsky (2002)
10.1089/104454904323145227
Molecular and cellular control of T1/T2 immunity at the interface between antimicrobial defense and immune pathology.
A. Bot (2004)
10.1128/JVI.76.15.7832-7842.2002
Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine
R. Emeny (2002)
J. Microencapsul
10.1016/S0169-409X(98)00013-1
ISCOMs and other saponin based adjuvants.
Cox (1998)
10.1016/0264-410X(95)80010-B
Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations.
F. Stieneker (1995)
10.1111/j.1745-7254.2005.00078.x
Baculovirus as a highly efficient expression vector in insect and mammalian cells
Y. Hu (2005)
10.1016/S0169-409X(97)00049-5
Preparation of microspheres by the solvent evaporation technique.
McGinity (1997)
10.1016/J.VACCINE.2007.08.034
Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice.
W. Zhao (2007)
Comparison of tissue reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in swine.
B. Straw (1985)
10.1016/0264-410X(88)90013-8
Influenza virus ISCOMs: biochemical characterization.
B. Sundquist (1988)
displaying HPV 16 L 2 epitopes induces cross - neutralizing antibodies to HPV 11
A. Soliakov (2012)
Nuclear delivery of doxorubicin via folatetargeted liposomes with bypass
D. Goren (2000)
Cellular immune responses to human papillomavirus ( HPV ) - 16 L 1 in healthy volunteers immunized with recombinant HPV - 16 L 1 virus - like particles
M. F. Powell (2003)
Preparation, characterization, and biological analysis of liposomal
D. N. Waterhouse (2005)
Targeting of antigen to dendritic cells with poly(gammaglutamic acid) nanoparticles
T. Uto (2007)
10.1039/DF9511100055
A study of the nucleation and growth processes in the synthesis of colloidal gold
J. Turkevich (1951)
10.1016/j.vaccine.2009.03.047
Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration.
A. Caputo (2009)
10.1515/BC.1999.047
Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles
C. Y. Kang (1999)
10.1016/S0168-3659(00)00339-4
Biodegradable polymeric nanoparticles as drug delivery devices.
K. Soppimath (2001)
10.1016/j.imlet.2011.06.002
Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice.
T. Uto (2011)
10.1016/S0168-3659(03)00205-0
Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization.
E. Lee (2003)
10.4049/jimmunol.178.5.2979
Targeting of Antigen to Dendritic Cells with Poly(γ-Glutamic Acid) Nanoparticles Induces Antigen-Specific Humoral and Cellular Immunity1
T. Uto (2007)
10.1016/J.VACCINE.2006.06.005
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
S. Giannini (2006)
Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
D. Goren (2000)
10.2174/156720107782151269
Liposomal drug delivery systems: an update review.
A. Samad (2007)
10.1023/A:1018995124527
Chitosan-Gadopentetic Acid Complex Nanoparticles for Gadolinium Neutron-Capture Therapy of Cancer: Preparation by Novel Emulsion-Droplet Coalescence Technique and Characterization
H. Tokumitsu (2004)
10.1016/S0264-410X(00)00019-0
Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses.
M. Baca-Estrada (2000)
Poly d, l-lactide-co-glycolic acid (PLGA)encapsulated vaccine on immune system in Epinephelus bruneus
R. Harikrishnan (2012)
In vitro degradation and release profiles of poly-DL-lactidepoly(ethylene glycol) microspheres
X. Li (2000)
A papillomaviruslike particle (VLP) vaccine
K. Slupetzky (2007)
10.1016/j.vaccine.2011.06.068
Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
P. Pushko (2011)
10.1128/JVI.02052-06
Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus
Fu-Shi Quan (2007)
Vaccine delivery using nanoparticles
AE Citation Gregory (2013)
10.1371/journal.pone.0024438
Effects of Transport Inhibitors on the Cellular Uptake of Carboxylated Polystyrene Nanoparticles in Different Cell Lines
T. dos Santos (2011)
Liposomes preparation methods.
M. Riaz (1996)
10.1111/J.1470-8744.1988.TB00012.X
The requirement of lipids for the formation of immunostimulating complexes (iscoms)
K. Lovgren (1988)
10.1038/308457A0
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
B. Morein (1984)



This paper is referenced by
10.1007/978-1-4939-1417-3_8
ISCOMs as a Vaccine Delivery System
Hanne Mørck Nielsen (2015)
10.3233/HAB-160302
Adjuvants for Clostridium tetani and Clostridium diphtheriae vaccines updating.
Fatimah M Alshanqiti (2017)
10.3390/nano10050823
Development of Polyelectrolyte Complexes for the Delivery of Peptide-Based Subunit Vaccines against Group A Streptococcus.
Lili Zhao (2020)
10.1016/j.pharmthera.2017.03.006
Gold nanoparticles, radiations and the immune system: Current insights into the physical mechanisms and the biological interactions of this new alliance towards cancer therapy
N. Dimitriou (2017)
10.1007/978-81-322-2607-9_16
Moving Forward: Expected Opportunities for the Development of New Therapeutic Agents Based on Nanotechnologies
F. F. Knapp (2016)
10.1080/14760584.2017.1355733
Calcium phosphate nanoparticles as a new generation vaccine adjuvant
Yahua Lin (2017)
10.1016/j.copbio.2013.11.014
Biological nanoparticles and their influence on organisms.
S. Stanley (2014)
10.1038/s41565-020-0732-3
Immune-mediated approaches against COVID-19
H. Florindo (2020)
10.1007/978-1-4939-3121-7_22
Nanomedicine and Infection
Takami Akagi (2016)
10.1007/978-3-030-01881-8_3
Poly-lactide/Poly-lactide-co-glycolide-Based Delivery System for Bioactive Compounds Against Microbes
R. Kumar (2019)
10.1186/s11671-018-2457-x
Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties
A. Sukhanova (2018)
10.1016/J.JDDST.2018.07.020
Immunogenicity of multi-walled carbon nanotubes functionalized with recombinant protective antigen domain 4 toward development of a nanovaccine against anthrax
F. Karimi (2018)
10.4155/ppa.15.38
Recent advances in vaccine delivery.
A. S. Cordeiro (2016)
10.22034/iji.2020.80296
Protective Potential of Conjugated P. aeruginosa LPS -PLGA Nanoparticles in Mice as a Nanovaccine.
Leila Safari Zanjani (2020)
10.1016/j.biomaterials.2014.04.010
Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen.
V. Temchura (2014)
10.3390/antib5040020
Systemic and Mucosal Antibody Responses to Soluble and Nanoparticle-Conjugated Antigens Administered Intranasally
Savannah E. Howe (2016)
10.1016/j.colsurfb.2015.07.079
Cationic micelle based vaccine induced potent humoral immune response through enhancing antigen uptake and formation of germinal center.
Z. Luo (2015)
Biotinylated peptide nanofibers for modulating the immune response
Şehmus Tohumeken (2016)
10.1007/978-3-030-35910-2_7
Oral Vaccine Delivery: The Coming Age of Particulate Vaccines to Elicit Mucosal Immunity
Rikhav P. Gala (2020)
10.1016/j.actbio.2018.08.002
Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
J. Jin (2018)
10.1002/mabi.201900042
Mannose-Modified Serum Exosomes for the Elevated Uptake to Murine Dendritic Cells and Lymphatic Accumulation.
E. S. Choi (2019)
10.1016/j.vaccine.2015.03.096
Advances and challenges in mucosal adjuvant technology.
D. Newsted (2015)
10.4172/2332-0877.1000141
Evaluation of Stearylamine-Modified Liposomes for the Oral Vaccine Adjuvant
Shinobu Watarai (2014)
10.1016/j.nano.2019.102073
Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells.
Verónica Durán (2019)
10.1016/j.actbio.2018.09.026
A systematic electron microscopic study on the uptake of barium sulphate nano-, submicro-, microparticles by bone marrow-derived phagocytosing cells.
Viktoriya Sokolova (2018)
10.1016/B978-0-12-811924-2.00019-5
Current and New Approaches for Mucosal Vaccine Delivery
J. Rhee (2020)
10.3389/fimmu.2018.01093
Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles
Young-Seok Kim (2018)
10.18869/acadpub.umj.28.4.33
Evaluation of proliferation and survival of spleen immune cells treated by Deacetylchitin nanoparticles on breast cancer mouse model
N. Soleimani (2017)
10.1002/wnan.1383
Virus-based nanoparticles as platform technologies for modern vaccines.
K. Lee (2016)
10.1016/j.biomaterials.2014.10.043
Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response.
S. Rahimian (2015)
10.1128/CVI.00738-13
Novel Catanionic Surfactant Vesicle Vaccines Protect against Francisella tularensis LVS and Confer Significant Partial Protection against F. tularensis Schu S4 Strain
K. Richard (2013)
Size regulates particulate adjuvant induced IL-10 and IL-12p70 production
S. Mccluskey (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar